Gut microbiome is not associated with mild cognitive impairment in Parkinson’s disease

Velma T.E. Aho; Matthias Klee; Zied Landoulsi; Anna Heintz-Buschart; Lukas Pavelka; Anja K. Leist; Rejko Krüger; Patrick May; Paul Wilmes; Geeta Acharya; Gloria Aguayo; Myriam Alexandre; Muhammad Ali; Wim Ammerlann; Giuseppe Arena; Michele Bassis; Roxane Batutu; Katy Beaumont; Sibylle Béchet; Guy Berchem; Alexandre Bisdorff; Ibrahim Boussaad; David Bouvier; Lorieza Castillo; Gessica Contesotto; Nancy De Bremaeker; Brian Dewitt; Nico Diederich; Rene Dondelinger; Nancy E. Ramia; Angelo Ferrari; Katrin Frauenknecht; Joëlle Fritz; Carlos Gamio; Manon Gantenbein; Piotr Gawron; Laura Georges; Soumyabrata Ghosh; Marijus Giraitis; Enrico Glaab; Martine Goergen; Elisa Gómez De Lope; Jérôme Graas; Mariella Graziano; Valentin Groues; Anne Grünewald; Gaël Hammot; Anne Marie Hanff; Linda Hansen; Michael Heneka; NCER-PD Consortium

doi:10.1038/s41531-024-00687-1

Gut microbiome is not associated with mild cognitive impairment in Parkinson’s disease

Velma T.E. Aho^*, Matthias Klee, Zied Landoulsi, Anna Heintz-Buschart, Lukas Pavelka, Anja K. Leist, Rejko Krüger, Patrick May, Paul Wilmes, Geeta Acharya, Gloria Aguayo, Myriam Alexandre, Muhammad Ali, Wim Ammerlann, Giuseppe Arena, Michele Bassis, Roxane Batutu, Katy Beaumont, Sibylle Béchet, Guy BerchemAlexandre Bisdorff, Ibrahim Boussaad, David Bouvier, Lorieza Castillo, Gessica Contesotto, Nancy De Bremaeker, Brian Dewitt, Nico Diederich, Rene Dondelinger, Nancy E. Ramia, Angelo Ferrari, Katrin Frauenknecht, Joëlle Fritz, Carlos Gamio, Manon Gantenbein, Piotr Gawron, Laura Georges, Soumyabrata Ghosh, Marijus Giraitis, Enrico Glaab, Martine Goergen, Elisa Gómez De Lope, Jérôme Graas, Mariella Graziano, Valentin Groues, Anne Grünewald, Gaël Hammot, Anne Marie Hanff, Linda Hansen, Michael Heneka, NCER-PD Consortium

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Gut microbiome differences between people with Parkinson’s disease (PD) and control subjects without Parkinsonism are widely reported, but potential alterations related to PD with mild cognitive impairment (MCI) have yet to be comprehensively explored. We compared gut microbial features of PD with MCI (n = 58) to cognitively unimpaired PD (n = 60) and control subjects (n = 90) with normal cognition. Our results did not support a specific microbiome signature related to MCI in PD.

Original language	English
Article number	78
Journal	npj Parkinson's Disease
Volume	10
Issue number	1
DOIs	https://doi.org/10.1038/s41531-024-00687-1
Publication status	Published - 1 Dec 2024

Access to Document

10.1038/s41531-024-00687-1Licence: CC BY

Cite this

Aho, V. T. E., Klee, M., Landoulsi, Z., Heintz-Buschart, A., Pavelka, L., Leist, A. K., Krüger, R., May, P., Wilmes, P., Acharya, G., Aguayo, G., Alexandre, M., Ali, M., Ammerlann, W., Arena, G., Bassis, M., Batutu, R., Beaumont, K., Béchet, S., ... NCER-PD Consortium (2024). Gut microbiome is not associated with mild cognitive impairment in Parkinson’s disease. npj Parkinson's Disease, 10(1), Article 78. https://doi.org/10.1038/s41531-024-00687-1

@article{5fe60ce98d2947dba4a5cb8f22f5c3f2,

title = "Gut microbiome is not associated with mild cognitive impairment in Parkinson{\textquoteright}s disease",

abstract = "Gut microbiome differences between people with Parkinson{\textquoteright}s disease (PD) and control subjects without Parkinsonism are widely reported, but potential alterations related to PD with mild cognitive impairment (MCI) have yet to be comprehensively explored. We compared gut microbial features of PD with MCI (n = 58) to cognitively unimpaired PD (n = 60) and control subjects (n = 90) with normal cognition. Our results did not support a specific microbiome signature related to MCI in PD.",

author = "Aho, {Velma T.E.} and Matthias Klee and Zied Landoulsi and Anna Heintz-Buschart and Lukas Pavelka and Leist, {Anja K.} and Rejko Kr{\"u}ger and Patrick May and Paul Wilmes and Geeta Acharya and Gloria Aguayo and Myriam Alexandre and Muhammad Ali and Wim Ammerlann and Giuseppe Arena and Michele Bassis and Roxane Batutu and Katy Beaumont and Sibylle B{\'e}chet and Guy Berchem and Alexandre Bisdorff and Ibrahim Boussaad and David Bouvier and Lorieza Castillo and Gessica Contesotto and {De Bremaeker}, Nancy and Brian Dewitt and Nico Diederich and Rene Dondelinger and Ramia, {Nancy E.} and Angelo Ferrari and Katrin Frauenknecht and Jo{\"e}lle Fritz and Carlos Gamio and Manon Gantenbein and Piotr Gawron and Laura Georges and Soumyabrata Ghosh and Marijus Giraitis and Enrico Glaab and Martine Goergen and {De Lope}, {Elisa G{\'o}mez} and J{\'e}r{\^o}me Graas and Mariella Graziano and Valentin Groues and Anne Gr{\"u}newald and Ga{\"e}l Hammot and Hanff, {Anne Marie} and Linda Hansen and Michael Heneka and {NCER-PD Consortium}",

note = "Funding Information: We would like to thank all participants of the Luxembourg Parkinson\u2019s Study for their important support of our research. Furthermore, we acknowledge the joint effort of the National Centre of Excellence in Research on Parkinson\u2019s Disease (NCER-PD) Consortium members from the partner institutions Luxembourg Centre for Systems Biomedicine, Luxembourg Institute of Health, Centre Hospitalier de Luxembourg, and Laboratoire National de Sant\u00E9 generally contributing to the Luxembourg Parkinson\u2019s Study. Data used in the preparation of this manuscript were obtained from the National Centre of Excellence in Research on Parkinson\u2019s Disease (NCER-PD). The National Centre of Excellence in Research on Parkinson\u2019s Disease (NCER-PD) is funded by the Luxembourg National Research Fund (FNR/NCER13/BM/11264123). The work was supported by the PEARL program (FNR/P13/6682797 to R.K.), MotaSYN (12719684 to R.K.), MAMaSyn (to R.K.), the FNR/DFG Core INTER (ProtectMove, FNR11250962 to P.M.). P.W. acknowledges funding from the European Research Council under the European Union\u2019s Horizon 2020 research and innovation program (no. 863664). A.K.L., R.K., and P.W. acknowledge the financial support of the Institute for Advanced Studies of the University of Luxembourg through an AUDACITY grant (ref. no. MCI-BIOME_2019). The funders played no role in the study design, data collection, analysis and interpretation of data, or the writing of this manuscript. For the purpose of open access, and in fulfillment of the obligations arising from the grant agreement of the Luxembourg National Research Fund, the authors have applied a Creative Commons Attribution 4.0 International (CC BY 4.0) license to any Author Accepted Manuscript version arising from this submission. The sequence data analyses for this study were carried out using the HPC facilities of the University of Luxembourg. Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = dec,

day = "1",

doi = "10.1038/s41531-024-00687-1",

language = "English",

volume = "10",

journal = "npj Parkinson's Disease",

issn = "2373-8057",

publisher = "Springer Nature",

number = "1",

}

Aho, VTE, Klee, M, Landoulsi, Z, Heintz-Buschart, A, Pavelka, L, Leist, AK, Krüger, R, May, P, Wilmes, P, Acharya, G, Aguayo, G, Alexandre, M, Ali, M, Ammerlann, W, Arena, G, Bassis, M, Batutu, R, Beaumont, K, Béchet, S, Berchem, G, Bisdorff, A, Boussaad, I, Bouvier, D, Castillo, L, Contesotto, G, De Bremaeker, N, Dewitt, B, Diederich, N, Dondelinger, R, Ramia, NE, Ferrari, A, Frauenknecht, K, Fritz, J, Gamio, C, Gantenbein, M, Gawron, P, Georges, L, Ghosh, S, Giraitis, M, Glaab, E, Goergen, M, De Lope, EG, Graas, J, Graziano, M, Groues, V, Grünewald, A, Hammot, G, Hanff, AM, Hansen, L, Heneka, M & NCER-PD Consortium 2024, 'Gut microbiome is not associated with mild cognitive impairment in Parkinson’s disease', npj Parkinson's Disease, vol. 10, no. 1, 78. https://doi.org/10.1038/s41531-024-00687-1

TY - JOUR

T1 - Gut microbiome is not associated with mild cognitive impairment in Parkinson’s disease

AU - Aho, Velma T.E.

AU - Klee, Matthias

AU - Landoulsi, Zied

AU - Heintz-Buschart, Anna

AU - Pavelka, Lukas

AU - Leist, Anja K.

AU - Krüger, Rejko

AU - May, Patrick

AU - Wilmes, Paul

AU - Acharya, Geeta

AU - Aguayo, Gloria

AU - Alexandre, Myriam

AU - Ali, Muhammad

AU - Ammerlann, Wim

AU - Arena, Giuseppe

AU - Bassis, Michele

AU - Batutu, Roxane

AU - Beaumont, Katy

AU - Béchet, Sibylle

AU - Berchem, Guy

AU - Bisdorff, Alexandre

AU - Boussaad, Ibrahim

AU - Bouvier, David

AU - Castillo, Lorieza

AU - Contesotto, Gessica

AU - De Bremaeker, Nancy

AU - Dewitt, Brian

AU - Diederich, Nico

AU - Dondelinger, Rene

AU - Ramia, Nancy E.

AU - Ferrari, Angelo

AU - Frauenknecht, Katrin

AU - Fritz, Joëlle

AU - Gamio, Carlos

AU - Gantenbein, Manon

AU - Gawron, Piotr

AU - Georges, Laura

AU - Ghosh, Soumyabrata

AU - Giraitis, Marijus

AU - Glaab, Enrico

AU - Goergen, Martine

AU - De Lope, Elisa Gómez

AU - Graas, Jérôme

AU - Graziano, Mariella

AU - Groues, Valentin

AU - Grünewald, Anne

AU - Hammot, Gaël

AU - Hanff, Anne Marie

AU - Hansen, Linda

AU - Heneka, Michael

AU - NCER-PD Consortium

N1 - Funding Information: We would like to thank all participants of the Luxembourg Parkinson\u2019s Study for their important support of our research. Furthermore, we acknowledge the joint effort of the National Centre of Excellence in Research on Parkinson\u2019s Disease (NCER-PD) Consortium members from the partner institutions Luxembourg Centre for Systems Biomedicine, Luxembourg Institute of Health, Centre Hospitalier de Luxembourg, and Laboratoire National de Sant\u00E9 generally contributing to the Luxembourg Parkinson\u2019s Study. Data used in the preparation of this manuscript were obtained from the National Centre of Excellence in Research on Parkinson\u2019s Disease (NCER-PD). The National Centre of Excellence in Research on Parkinson\u2019s Disease (NCER-PD) is funded by the Luxembourg National Research Fund (FNR/NCER13/BM/11264123). The work was supported by the PEARL program (FNR/P13/6682797 to R.K.), MotaSYN (12719684 to R.K.), MAMaSyn (to R.K.), the FNR/DFG Core INTER (ProtectMove, FNR11250962 to P.M.). P.W. acknowledges funding from the European Research Council under the European Union\u2019s Horizon 2020 research and innovation program (no. 863664). A.K.L., R.K., and P.W. acknowledge the financial support of the Institute for Advanced Studies of the University of Luxembourg through an AUDACITY grant (ref. no. MCI-BIOME_2019). The funders played no role in the study design, data collection, analysis and interpretation of data, or the writing of this manuscript. For the purpose of open access, and in fulfillment of the obligations arising from the grant agreement of the Luxembourg National Research Fund, the authors have applied a Creative Commons Attribution 4.0 International (CC BY 4.0) license to any Author Accepted Manuscript version arising from this submission. The sequence data analyses for this study were carried out using the HPC facilities of the University of Luxembourg. Publisher Copyright: © The Author(s) 2024.

PY - 2024/12/1

Y1 - 2024/12/1

N2 - Gut microbiome differences between people with Parkinson’s disease (PD) and control subjects without Parkinsonism are widely reported, but potential alterations related to PD with mild cognitive impairment (MCI) have yet to be comprehensively explored. We compared gut microbial features of PD with MCI (n = 58) to cognitively unimpaired PD (n = 60) and control subjects (n = 90) with normal cognition. Our results did not support a specific microbiome signature related to MCI in PD.

AB - Gut microbiome differences between people with Parkinson’s disease (PD) and control subjects without Parkinsonism are widely reported, but potential alterations related to PD with mild cognitive impairment (MCI) have yet to be comprehensively explored. We compared gut microbial features of PD with MCI (n = 58) to cognitively unimpaired PD (n = 60) and control subjects (n = 90) with normal cognition. Our results did not support a specific microbiome signature related to MCI in PD.

U2 - 10.1038/s41531-024-00687-1

DO - 10.1038/s41531-024-00687-1

M3 - Article

SN - 2373-8057

VL - 10

JO - npj Parkinson's Disease

JF - npj Parkinson's Disease

IS - 1

M1 - 78

ER -

Gut microbiome is not associated with mild cognitive impairment in Parkinson’s disease

Abstract

Access to Document

Fingerprint

Cite this